Zura Bio Limited

NasdaqCM ZURA

Zura Bio Limited Cash and Short-Term Investments for the quarter ending September 30, 2024

Zura Bio Limited Cash and Short-Term Investments is NA for the quarter ending September 30, 2024. Cash and short-term investments are the sum of cash and short-term investments, representing the company's liquid assets.
Key data
Date Cash and Short-Term Investments Receivables Inventory Goodwill
Market news
NasdaqCM: ZURA

Zura Bio Limited

CEO Mr. Robert Lisicki
IPO Date March 21, 2023
Location United States
Headquarters 4225 Executive Square
Employees 14
Sector Health Care
Industries
Biotechnology Pharmaceuticals
Description

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in San Diego, California.

StockViz Staff

January 15, 2025

Any question? Send us an email